In January 2009, The American Society of Clinical Oncology (ASCO) issued their first provisional clinical opinion (PCO) recommending that all patients with mCRC who are candidates for anti-EGFR monoclonal antibody therapy should undergo testing for KRAS mutations and that patients with KRAS mutations in codons 12 or 13 should not receive anti-EGFR monoclonal antibody therapy as part of their treatment.85 The PCO is based on studies identified in searches of the MEDLINE database (through October 2008) and the 2008 ASCO Annual Meeting presentations by the Blue Cross and Blue Shield Association Technology Evaluation Center. Importantly, the PCO is therefore based on studies that used assays capable of detecting KRAS mutations in codons 12 or 13 only and did not include a comparison of the specificity or sensitivity of assays currently available for KRAS mutation analysis. In addition to the ASCO PCO, the National Comprehensive Cancer Network has updated its guidelines with a recommendation that therapies including panitumumab or cetuximab be limited to patients with wild-type KRAS for patients with advanced or metastatic colon or rectal cancer.86,87 The US Food and Drug Administration has recently approved revisions to the prescribing information for panitumumab and cetuximab that now state that their use is not recommended in patients with colorectal tumors that have KRAS mutations in codons 12 or 13.31,34
An important aspect in the determination of concordance between different assay techniques is the selection of a gold-standard method for the determination of reference standards. Such a method should be able to accurately quantify the amount of the specific analyte in question. Emulsion PCR used in combination with picotiter-plate sequencing offers rapid and sensitive screening of entire genomes or genome subregions and may represent such a gold standard in gene mutation testing.91 In this approach, developed by Roche Diagnostics Corporation/454 Life Sciences (Branford, CT, USA), specific genomic regions of interest are amplified by PCR with primers incorporating universal tags using PCR on DNA extracted from tissue [eg, formalin-fixed paraffin-embedded (FFPE) tissue], with specific linker sequences being added by a subsequent round of PCR, and then hybridized to beads using limiting dilutions to enable 1 amplimer to bind per bead. After clonal amplification by emulsion PCR, the beads are dispersed into a picotiter-plate and subjected to pyrosequencing, during which nucleotide incorporation is measured as luminescence. The technology enables multiple reads of each amplimer to be measured, thereby enabling accurate quantitation of the number of genome equivalents of wild-type or mutant amplimers. Thus, this technology can be used to accurately determine the number of mutant genome equivalents in a given sample, providing an accurate “gold standard” sample that can be used in the evaluation of other assays. A recent study assessing comparability between 4 commercial KRAS tests and an internal direct sequencing core laboratory using colorectal tumor samples found that some tests are in close agreement, but others are not.92 Similar results were observed in another study that compared KRAS testing techniques in clinical colorectal cancer samples.93 Furthermore, a recent study showed that cycle sequencing and real-time PCR were reliable and comparable methods for KRAS mutation testing, with the caveat that the sample must contain a sufficient proportion of tumor cells.94
Agreement among pathologists and oncologists on a standardized method of comparing and validating KRAS mutation testing methods is essential for the future implementation of KRAS testing in the clinic. Studies have showed some lack of comparability between assays.92 This lack of agreement is unsurprising, but it raises the question of how pathologists should assess concordance between KRAS tests or conduct proficiency testing. It has been proposed that concordance testing should consist of a 2-step process using 2 separate sets of samples. The first step would determine the ability of a laboratory to extract DNA from a range of FFPE tumor blocks in a form suitable for the assay used by the laboratory (typically PCR-amplifiable DNA). The second step would test the ability of the laboratory to identify mutations in sample extract mixtures that have accurately determined amounts of mutant and wild-type KRAS alleles. For example, one method for accurately determining the amount of mutant KRAS in an FFPE sample is emulsion PCR picotiter-plate sequencing as carried out on the Roche 454 sequencer91 that would enable an accurate ratio of mutant to wild-type alleles to be determined within a tumor extract. In addition, such extracts could be mixed with FFPE extracts containing only wild-type alleles to allow a range of samples to be generated, each with varying levels of mutant to wild-type alleles spanning a variety of mutant alleles and at levels close to the target sensitivity (cutoff) required for clinical utility. If prepared by a reference laboratory, these extracts could have widespread use.
Another important consideration for pathologists and the oncology community is the impact of mutations in other genes on clinical decision making. Even among patients with wild-type KRAS, a large proportion do not respond to EGFR-targeted monoclonal antibody therapies.4,98 Therefore, should routine pretreatment practice also include testing for mutations in other genes downstream of the EGFR, such as BRAF? In a retrospective analysis of patients with mCRC treated with panitumumab or cetuximab, BRAF V600E mutations resulted in a lack of response to treatment and significantly shorter progression-free survival and overall survival compared with wild-type BRAF.99 Another gene that may affect patient response to anti-EGFR therapy is PIK3CA. A recent study of patients with curatively resected colorectal cancer showed that PIK3CA mutations were associated with increased cancer-specific mortality [hazard ratio (HR), 2.23; 95% CI, 1.21-4.11]. The association between PIK3CA mutations and increased mortality was strongest among patients with wild-type KRAS (HR, 3.80; 95% CI, 1.56-9.27) but was not observed in patients with KRAS mutations (HR, 1.25; 95% CI, 0.52-2.96). Mutations in PIK3CA have also been shown to confer resistance to anti-EGFR therapies among patients with mCRC.100 In that study, among 110 patients with mCRC who received treatment with either panitumumab or cetuximab, 15 (13.6%) had mutations in PIK3CA. None of the patients with PIK3CA mutations had objective responses (P=0.038). In addition, PIK3CA mutations were associated with shorter progression-free survival (P=0.0035) compared with wild-type PIK3CA. Although further studies will be necessary to assess their utility as predictors of response to anti-EGFR therapy, it is possible that mutational analyses will extend beyond KRAS to include BRAF and PIK3CA.
The authors thank Ali Hassan, PhD, and Benjamin Scott, PhD (Complete Healthcare Communications, Inc., Chadds Ford, PA), whose work was funded by Amgen Inc. (Thousand Oaks, CA), for assistance in the preparation of this manuscript.
1. Green MR. Targeting targeted therapy. N Engl J Med. 2004;350:2191–2193.
2. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab
plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
. J Clin Oncol. 2007;25:1658–1664.
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab
for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–2048.
4. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS
is required for panitumumab
efficacy in patients with metastatic colorectal cancer
. J Clin Oncol. 2008;26:1626–1634.
5. Lievre A, Bachet JB, Boige V, et al. KRAS
mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
. J Clin Oncol. 2008;26:374–379.
6. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor
antibody therapies. Cancer Res. 2007;67:2643–2648.
7. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer
patients treated with cetuximab
. J Clin Oncol. 2007;25:3230–3237.
8. Di Fiore F, Van Cutsem E, Laurent-Puig P, et al. Role of KRAS
mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab
plus irinotecan for a metastatic colorectal cancer
: analysis of 281 individual data from published series [abstract]. J Clin Oncol. 2008;26:4035.
9. Cervantes T, Macarulla T, Martinelli E, et al. Correlation of KRAS status [wild type (wt) vs. mutant (mt)] with efficacy to first-line cetuximab
in a study of cetuximab
single agent followed by cetuximab
+FOLFIRI in patients (pts) with metastatic colorectal cancer
(mCRC) [abstract]. J Clin Oncol. 2008;26:4129.
10. Finocchiaro G, Cappuzzo F, Jänne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab
sensitivity in colorectal cancer [abstract]. J Clin Oncol. 2007;25(18S):4021.
11. Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer
(mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab
(q1w): the EVEREST experience (preliminary data) [abstract]. J Clin Oncol. 2008;26:4001.
12. Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer
alone. Clin Colorectal Cancer. 2008;7:184–190.
13. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor
(EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–286.
14. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab
efficacy in metastatic colorectal cancer
patients. Br J Cancer. 2007;97:1139–1145.
15. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab
therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995.
16. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer
treated by cetuximab
plus chemotherapy. Br J Cancer. 2007;96:1166–1169.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab
in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765.
18. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab
in the first-line treatment of metastatic colorectal cancer
. J Clin Oncol. 2009;27:663–671.
19. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab
and chemotherapy as initial treatment for metastatic colorectal cancer
. N Engl J Med. 2009;360:1408–1417.
20. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–1174.
21. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137.
22. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16:5276–5287.
23. Arcaro A, Zvelebil MJ, Wallasch C, et al. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol. 2000;20:3817–3830.
24. Coffer PJ, Kruijer W. EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem Biophys Res Commun. 1995;210:74–81.
25. Karihaloo A, O'Rourke DA, Nickel C, et al. Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis. J Biol Chem. 2001;276:9166–9173.
26. Giehl K, Skripczynski B, Mansard A, et al. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene. 2000;19:2930–2942.
27. Goldstein NS, Armin M. Epidermal growth factor receptor
immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331–1346.
28. Messa C, Russo F, Caruso MG, et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998;37:285–289.
29. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144.
30. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor
and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(10 suppl):2379–2385.
31. Vectibix® (panitumumab
). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc.; 2009.
32. Vectibix European Public Assessment Report, Scientific Discussion
. London, UK: European Medicines Agency; 2008.
33. Vectibix® (panitumumab
). Full Prescribing Information. Mississauga, ON, Canada: Amgen Inc.; 2008.
34. Erbitux® (cetuximab
). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
35. Erbitux European Public Assessment Report, Scientific Discussion.
London, UK: European Medicines Agency; 2009.
36. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor
for cancer treatment. J Natl Cancer Inst. 2003;95:851–867.
37. Tarceva® (erlotinib). Full Prescribing Information. Melville, NY: OSI Pharmaceuticals, Inc.; 2008.
38. Ellis RW, DeFeo D, Furth ME, et al. Mouse cells contain two distinct ras gene mRNA species that can be translated into a p21 onc protein. Mol Cell Biol. 1982;2:1339–1345.
39. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–465.
40. Yamashita T, Yamamoto K, Kikuchi A, et al. Purification and characterization of c-Ki-ras p21 from bovine brain crude membranes. J Biol Chem. 1988;263:17181–17188.
41. Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A. 1982;79:3637–3640.
42. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153–208.
43. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell. 1993;73:611–620.
44. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.
45. Gibbs JB, Schaber MD, Allard WJ, et al. Purification of ras GTPase activating protein from bovine brain. Proc Natl Acad Sci U S A. 1988;85:5026–5030.
46. Sharpe CC, Dockrell ME, Scott R, et al. Evidence of a role for Ki-Ras in the stimulated proliferation of renal fibroblasts. J Am Soc Nephrol. 1999;10:1186–1192.
47. Clyde-Smith J, Silins G, Gartside M, et al. Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor. J Biol Chem. 2000;275:32260–32267.
48. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One. 2009;4:e5717.
49. Tchernitsa OI, Sers C, Zuber J, et al. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene. 2004;23:4536–4555.
50. Pohl G, Ho CL, Kurman RJ, et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 2005;65:1994–2000.
51. Tang Y, Zhou H, Chen A, et al. The Akt proto-oncogene links Ras to Pak and cell survival signals. J Biol Chem. 2000;275:9106–9109.
53. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308.
54. Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277:333–338.
55. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor
(EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007;109:1561–1569.
56. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226–3235.
57. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor
and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–5909.
58. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–696.
59. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90:675–684.
61. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532.
62. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 2001;19:299–304.
63. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002;13:1438–1446.
64. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–989.
65. Bouzourene H, Gervaz P, Cerottini JP, et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer. 2000;36:1008–1015.
66. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 1994;54:5523–5526.
67. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303.
68. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–297.
69. Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst. 1993;85:2004–2007.
70. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14:4830–4835.
71. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008;26:4217–4219.
72. Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer. 1992;28A:1115–1120.
73. Schimanski CC, Linnemann U, Berger MR. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res. 1999;59:5169–5175.
74. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991;49:875–879.
75. Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325:784–791.
76. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer. 1992;52:30–33.
77. Al-Mulla F, Going JJ, Sowden THH, et al. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998;185:130–138.
78. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270–1275.
79. Monzon FA, Ogino S, Hammond ME, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer
. Arch Pathol Lab Med. 2009;133:1600–1606.
80. Losi L, Baisse B, Bouzourene H, et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis. 2005;26:916–922.
81. Baisse B, Bouzourene H, Saraga EP, et al. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer. 2001;93:346–352.
82. Amado RG, Wolf M, Freeman D, et al. Association of KRAS
mutational status and efficacy of panitumumab
monotherapy for the treatment (tx) of metastatic colorectal cancer
(mcrc): results of pooled data from 4 clinical studies [abstract]. Ann Oncol. 2008;19(S8):viii126.
83. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472–1478.
84. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab
in metastatic colorectal cancer
: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst. 2009;101:1182–1192.
85. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor
monoclonal antibody therapy. J Clin Oncol. 2009;27:2091–2096.
86. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer v.2.2009. Fort Washington, PA: National Comprehensive Cancer Network; 2009.
87. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer v.2.2009. Fort Washington, PA: National Comprehensive Cancer Network; 2009.
88. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417–431.
89. Perspectives on Emerging Technology (POET). Report: KRAS Mutation Testing for Colorectal Cancer (CRC). Northfield, IL: College of American Pathologists; 2009.
90. Poehlmann A, Kuester D, Meyer F, et al. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract. 2007;203:489–497.
91. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009;55:641–658.
92. Juan T, Suggs S, Wolf M, et al. A comparability study of 4 commercial KRAS tests. Presented at: Annual Meeting of the American Association of Cancer Researchers; April 12-14, 2008; San Diego, CA.
93. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS
mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11:543–552.
94. Tol J, Dijkstra JR, Vink-Borger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. 2009; [Epub ahead of print].
95. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor
2 testing in breast cancer. J Clin Oncol. 2007;25:118–145.
96. Medicare, medicaid, and CLIA programs; laboratory requirements relating to quality systems and certain personnel qualifications; final rule. Vol 68: U.S. Department of Health and Human Services Federal Register; 2003:3640–3714.
97. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab
plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
. Br J Cancer. 2009;101:715–721.
98. Freeman D, Amado R, Wolf M, et al. Efficacy of panitumumab
monotherapy in relation to KRAS
mutational status for treating metastatic colorectal cancer
(mCRC) from four clinical studies [abstract]. Presented at: ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer; October 30-November 1, 2008; Hollywood, FL.
99. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab
in metastatic colorectal cancer
. J Clin Oncol. 2008;26:5705–5712.
100. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–1857.